ARGX vs MDGL
argenx SE vs Madrigal Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
MDGL
Madrigal Pharmaceuticals, Inc.
56
Watch
| Metric | ARGX | MDGL |
|---|
| AI Score |
69
|
56
|
| Price |
$864.40
|
$535.01
|
| P/E Ratio |
31.34×
|
-41.53×
|
| ROE |
17.6%
|
-47.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
91.5%
|
| Debt / Equity |
0.01×
|
0.66×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
60.0
|
| Beta |
-0.022
|
-1.003
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus MDGL.
ARGX leads by 13 points.
ARGX scores 69/100 (Buy) versus MDGL at 56/100 (Watch).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
MDGL Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 149.0% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 21.9x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 149.0% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 21.9x prices in significant intangible value — Value
- ROE of only -56.6% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical